Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 3076 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Alnylam and Takeda join hands in RNAi therapeutics

This collaboration provides Takeda with broad, worldwide, non-exclusive access to and enablement with Alnylam’s RNAi therapeutics platform technology and intellectual property in the fields of oncology and metabolic

Shire wins approval for Elaprase in Brazil

Elaprase, developed by Shire Human Genetic Therapies (HGT), a business unit of Shire focused on genetic diseases, is said to be the first and only enzyme replacement therapy